Host-targeting agents in the treatment of hepatitis C: a beginning and an end?
about
Harnessing Mechanistic Knowledge on Beneficial Versus Deleterious IFN-I Effects to Design Innovative Immunotherapies Targeting Cytokine Activity to Specific Cell TypesSuppression of La antigen exerts potential antiviral effects against hepatitis A virusEntry inhibitors: New advances in HCV treatmentHost-Targeting Agents to Prevent and Cure Hepatitis C Virus InfectionMonoclonal antibodies: Principles and applications of immmunodiagnosis and immunotherapy for hepatitis C virusGenetic variants at the IFNL3 locus and their association with hepatitis C virus infections reveal novel insights into host-virus interactionsCombinations of siRNAs against La Autoantigen with NS5B or hVAP-A Have Additive Effect on Inhibition of HCV ReplicationSeed Sequence-Matched Controls Reveal Limitations of Small Interfering RNA Knockdown in Functional and Structural Studies of Hepatitis C Virus NS5A-MOBKL1B InteractionThe inhibitory effects of anacardic acid on hepatitis C virus life cycleA novel small-molecule inhibitor of hepatitis C virus replication acts by suppressing signal transducer and activator of transcription 3.The Novel Cyclophilin Inhibitor CPI-431-32 Concurrently Blocks HCV and HIV-1 Infections via a Similar Mechanism of Action.Hepatitis C Virus Particle Assembly Involves Phosphorylation of NS5A by the c-Abl Tyrosine Kinase.Identification of Entry Factors Involved in Hepatitis C Virus Infection Based on Host-Mimicking Short Linear Motifs.Hepatitis C Virus-Induced Rab32 Aggregation and Its Implications for Virion Assembly.Identification of a novel epitope in the C terminus of hepatitis C virus-E2 protein that induces potent and cross-reactive neutralizing antibodies.Why highly effective drugs are not enough: the need for an affordable solution to eliminating HCV.Direct-acting antiviral agents for hepatitis C: structural and mechanistic insights.Hepatitis C virus: life cycle in cells, infection and host response, and analysis of molecular markers influencing the outcome of infection and response to therapy.The effects of CYP3A4 induction and inhibition on the pharmacokinetics of alisporivir in humans.Roles of the Mevalonate Pathway and Cholesterol Trafficking in Pulmonary Host Defense.Cellular fatty acid synthase is required for late stages of HIV-1 replication.Host-targeting therapies for hepatitis C virus infection: current developments and future applications.
P2860
Q21131160-03F8BBA3-1299-445D-A189-F35EB2E3A13BQ21131991-9A20201B-F152-4E56-A4CB-17AAC269E2F8Q26770817-C777DF4A-7938-4F85-ACF6-2BEB25EB38D4Q26779128-44D1542D-31DF-4AD5-8ADA-9A79EB35FFF8Q26783378-655FBA9D-E548-4EF9-8A6A-C02F00C16CCEQ27014831-594D4AF9-A3A6-42EB-92A3-343CDAD7A47BQ27469011-CBB27282-00A3-42A0-96BB-AFF67EA79513Q27684710-6DCC0864-FF55-418C-B3A2-16C1D77D9A22Q28543293-28C26B15-F473-4A25-89FF-DBEF79B2B47AQ35598686-605A8744-4BEC-40D1-BC27-D6DD658EC1D1Q35742761-56EF8945-7C6D-4CBE-A8E2-61C86A1F8914Q36065201-12856329-4C2D-4591-90E4-884AFC7214E7Q36262482-F87A41D2-AFA0-4D1B-9792-F4B7AA8F3F38Q37593216-5B869863-320D-4FF0-956B-94F5A7A21164Q38715557-2808C900-2C7E-44D5-91CD-9FFDD906F127Q38735359-EEBCECAF-BCE7-46AC-8DF9-AD56ED7D8317Q38826176-B6F761BE-9992-4F18-94A0-620184CBA484Q38945754-BD70C015-8F6D-4A46-9D6C-613D3E1654B6Q39810813-919653BF-9D09-4B97-A1F4-A3CF8809BBA7Q40835741-DFF72A77-C671-4117-A8BF-DC7E5A7A12DFQ41927731-87652C54-6340-4A90-B738-ED7A7E22FBE9Q55280981-8CC8D915-B947-4CB8-9D02-048F4C5CE051
P2860
Host-targeting agents in the treatment of hepatitis C: a beginning and an end?
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 30 September 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Host-targeting agents in the treatment of hepatitis C: a beginning and an end?
@en
Host-targeting agents in the treatment of hepatitis C: a beginning and an end?
@nl
type
label
Host-targeting agents in the treatment of hepatitis C: a beginning and an end?
@en
Host-targeting agents in the treatment of hepatitis C: a beginning and an end?
@nl
prefLabel
Host-targeting agents in the treatment of hepatitis C: a beginning and an end?
@en
Host-targeting agents in the treatment of hepatitis C: a beginning and an end?
@nl
P2093
P2860
P1433
P1476
Host-targeting agents in the treatment of hepatitis C: a beginning and an end?
@en
P2093
James M Baugh
Jose A Garcia-Rivera
Philippe A Gallay
P2860
P304
P356
10.1016/J.ANTIVIRAL.2013.09.020
P577
2013-09-30T00:00:00Z